August 17, 2015
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Ocular Therapeutix reports net loss of $10 million in second quarter
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Ocular Therapeutix reported a net loss of $10 million, or $0.45 per share, in the second quarter compared with a net loss of $6.4 million, or $2.10 per share, in the same quarter of 2014, according to a press release.
Operating expenses increased to $10.1 million from $6 million, and research and development expenses increased to $6.7 million from $4.3 million. The increase was attributed to personnel costs and clinical trials of Dextenza and OTX-TP.
Total revenue was $459,000 in the second quarter compared with $97,000 in the second quarter a year ago.
The company expects to announce top-line efficacy data of phase 2 and 3 trials of Dextenza and a phase 2b trial of OTX-TP in the fourth quarter.